LUCIUS 卢修斯 达拉非尼 Dabrafenib黑色素瘤

达拉非尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Dabrafenib

老挝国家食药监局批准上市
老挝国家药检所检测认证

黑色素瘤

Composilie:
Bach LuciDabea Crecile e
Each LuciDabra Capsule contains: 88.88mg Dabrafen
mesylate equivalent to Dabrafenib15

LUCĪUS

LuciDabra is a kimase inhib

PHARMACEUTICALS

the trtatment of nafiantun
melanoma with BRAF V600E masden
is will unresectable or metastatic
sidscated, in comola

Rx Only

the treatment of patients with mnre ios
BRAF V600E or V6OOK

LuciDabra

or v 600K mutations and involvement ofl
the treatinant sonn
ients with metastatic non-small cell l

Dabrafenib Capsules

FDA批准

acory locoregosal Ireatment optio
oi patients with wild-typec
cated for treatment
lype BRAF melanoma, wild-type BRA
Dosage and Uses
The recommended dousns.
twice daily. Teke LuciDabra at lesst & hour before or stleas
ded dosage of LuciDabra is 150 mg orally
erusted
d be swallowed whole & not chewed or

75mg

terages ina dry place and store at 20°C 1025°
Waraing

Keep medicine out of the reach of Children. Do n06
administered LociDabra in Pregnancy and Lactation patient
treatment.

PLEAGE OED DACK AGEINSE
TLEASE SEE PACKALE I
Maufachuad ond Marketed

权威认证

Thongmang village, Xaythany district
vientiane Capital. Laos
waring to ne sold by retail on prescription
by the phocogst ony, and as directed

120 Capsules

口碑质量

适应症:

一、单独使用:
用于治疗BRAF V600E突变的不可切除或转移性黑色素瘤患者。
二、与曲美替尼联合用于:

1、BRAF V600E或V600K突变的不可切除或转移性黑色素瘤患者的治疗;
2、BRAF V600E或V600K突变的黑色素瘤患者的辅助治疗;
3、BRAF V600E突变的转移性癌症(NSCLC)患者的治疗;
4、BRAF V600E突变的局部晚期或转移性癌症(ATC)患者的治疗。
推荐剂量:

1、每日口服两次,每次150mg;
2、空腹服用(餐前1小时或餐后2小时)。